Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.8%

1 terminated out of 21 trials

Success Rate

94.1%

+7.6% vs benchmark

Late-Stage Pipeline

33%

7 trials in Phase 3/4

Results Transparency

13%

2 of 16 completed with results

Key Signals

2 with results94% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (3)
P 2 (4)
P 3 (2)
P 4 (5)

Trial Status

Completed16
Unknown2
Withdrawn1
Active Not Recruiting1
Terminated1

Trial Success Rate

94.1%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT04862273Completed

CMR T1 Mapping for Diagnosis of Cardiac Amyloidosis

NCT03749551Completed

Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study

NCT03094143Not ApplicableActive Not Recruiting

Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS

NCT02599480Phase 2CompletedPrimary

Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure

NCT05713916Not ApplicableCompletedPrimary

Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy

NCT03315832Phase 2Withdrawn

Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study

NCT03482934Completed

Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate

NCT03415750Phase 4CompletedPrimary

Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants

NCT02973607Completed

Effects of a Reduction in Renal Function on Cardiovascular Structure and Function

NCT02444689Not ApplicableCompleted

EMPower: Electronic Media Powering Positive Health Changes in Youth

NCT02237339Phase 4Completed

Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?

NCT03180593Phase 4Completed

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

NCT00108082Phase 3CompletedPrimary

The CLEVER Study - Coreg And Left Ventricular Mass Regression

NCT00041418Completed

Cardiac MR of Subclinical CVD: Impact of Age

NCT00005373Completed

Racial Differences in the Coronary Microcirculation

NCT01976689Completed

New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation

NCT00616902Phase 3Terminated

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

NCT00989508Phase 2Unknown

Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy

NCT00552851Phase 4Unknown

Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant

NCT01144039Phase 4CompletedPrimary

Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair

Scroll to load more

Research Network

Activity Timeline